UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy

Blood, 2021-03, Vol.137 (12), p.1669-1678

2021

Volltextzugriff (PDF)

Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy

Annals of medicine (Helsinki), 2022-12, Vol.54 (1), p.1339-1349

2022

Volltextzugriff (PDF)

Optimizing the prescription doses and tolerability of systemic therapy in head and neck cancer patients

Current opinion in oncology, 2022-05, Vol.34 (3), p.204-211

Fuereder, Thorsten

2022

Volltextzugriff (PDF)

The Geriatric Nutritional Risk Index (GNRI) as a Prognostic Biomarker for Immune Checkpoint Inhibitor Response in Recurrent and/or Metastatic Head and Neck Cancer

Nutrients, 2023-02, Vol.15 (4), p.880

2023

Volltextzugriff (PDF)

Chemotherapy-associated oral microbiome changes in breast cancer patients

Frontiers in oncology, 2022-08, Vol.12, p.949071-949071

2022

Volltextzugriff (PDF)

EVI1 Promotes the Proliferation and Invasive Properties of Human Head and Neck Squamous Cell Carcinoma Cells

International journal of molecular sciences, 2022-01, Vol.23 (3), p.1050

2022

Volltextzugriff (PDF)

Cancer of unknown primary—state of the art

Memo - Magazine of European medical oncology, 2024-02, Vol.17 (1), p.30-34

Fuereder, Thorsten

2024

Volltextzugriff (PDF)

PD-L1 Expression on Tumor Cells Is Associated With a Poor Outcome in a Cohort of Caucasian Nasopharyngeal Carcinoma Patients

Frontiers in oncology, 2019-11, Vol.9, p.1334-1334

2019

Volltextzugriff (PDF)

Nasopharyngeal carcinoma: Essential news regarding current guidelines

Memo - Magazine of European medical oncology, 2023-09, Vol.16 (3), p.165-169

Fuereder, Thorsten

2023

Volltextzugriff (PDF)

DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma

Journal for immunotherapy of cancer, 2022-03, Vol.10 (3), p.e003420

2022

Volltextzugriff (PDF)

Essential news of current guidelines: head and neck squamous cell carcinoma

Memo - Magazine of European medical oncology, 2022-12, Vol.15 (4), p.278-281

Fuereder, Thorsten

2022

Volltextzugriff (PDF)

Dietary intervention for tertiary prevention in head and neck squamous cell carcinoma survivors: clinical and translational results of a randomized phase II trial

Frontiers in oncology, 2024-01, Vol.13, p.1321174-1321174

2024

Volltextzugriff (PDF)

KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.6505-6505

2020

Volltextzugriff (PDF)

SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic

ESMO open, 2020-09, Vol.5 (5), p.e000889, Article e000889

2020

Volltextzugriff (PDF)

Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study

Cancers, 2020-09, Vol.12 (9), p.2493

2020

Volltextzugriff (PDF)

Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients

Biomolecules (Basel, Switzerland), 2021-11, Vol.11 (11), p.1700

2021

Volltextzugriff (PDF)

Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation

Transplantation, 2007-02, Vol.83 (4), p.425-432

2007

Volltextzugriff (PDF)

Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers

Cancers, 2020-11, Vol.12 (11), p.3381

2020

Volltextzugriff (PDF)

ASCO 2021 highlights head and neck cancer: nasopharyngeal carcinoma

Memo - Magazine of European medical oncology, 2021-12, Vol.14 (4), p.331-334

Fuereder, Thorsten

2021

Volltextzugriff (PDF)

Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.6000-6000

2019

Volltextzugriff (PDF)

ASCO virtual meeting 2020: highlights head and neck cancer

Memo - Magazine of European medical oncology, 2021-03, Vol.14 (1), p.62-65

Fuereder, Thorsten

2021

Volltextzugriff (PDF)

Resistance to immune checkpoint inhibitors. Next steps and combinational approaches

Memo - Magazine of European medical oncology, 2019-06, Vol.12 (2), p.123-127

Fuereder, Thorsten

2019

Volltextzugriff (PDF)

Head and neck cancer revisited

Memo - Magazine of European medical oncology, 2023-09, Vol.16 (3), p.146-147

Füreder, Thorsten

2023

Volltextzugriff (PDF)

Immunotherapy for head and neck squamous cell carcinoma

Memo - Magazine of European medical oncology, 2016, Vol.9 (2), p.66-69

Fuereder, Thorsten

2016

Volltextzugriff (PDF)

Circulating endothelial progenitor cells in castration resistant prostate cancer: a randomized, controlled, biomarker study

PloS one, 2014-04, Vol.9 (4), p.e95310-e95310

2014

Volltextzugriff (PDF)

1 – 25 von 103

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(96)
Mit Volltextzugriff
(93)

Publikationsform

Artikel
(103)

Sprache

Englisch
(100)
Deutsch
(3)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(74)
Life Sciences & Biomedicine
(69)
Oncology
(53)
Humans
(38)
Medicine
(21)
Female
(20)
Medicine & Public Health
(19)
Immunotherapy
(18)
Cancer
(17)
Medicine/public Health
(17)
Chemotherapy
(14)
Patients
(14)
Retrospective Studies
(14)
Male
(13)
Head & Neck Cancer
(12)
Metastasis
(12)
Aged
(11)
Middle Aged
(11)
Cell Line, Tumor
(10)
Head And Neck Neoplasms - Drug Therapy
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy

Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy

Optimizing the prescription doses and tolerability of systemic therapy in head and neck cancer patients

The Geriatric Nutritional Risk Index (GNRI) as a Prognostic Biomarker for Immune Checkpoint Inhibitor Response in Recurrent and/or Metastatic Head and Neck Cancer

Chemotherapy-associated oral microbiome changes in breast cancer patients

EVI1 Promotes the Proliferation and Invasive Properties of Human Head and Neck Squamous Cell Carcinoma Cells

Cancer of unknown primary—state of the art

PD-L1 Expression on Tumor Cells Is Associated With a Poor Outcome in a Cohort of Caucasian Nasopharyngeal Carcinoma Patients

Nasopharyngeal carcinoma: Essential news regarding current guidelines

DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma

Essential news of current guidelines: head and neck squamous cell carcinoma

Dietary intervention for tertiary prevention in head and neck squamous cell carcinoma survivors: clinical and translational results of a randomized phase II trial

KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic

Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study

Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients

Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation

Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers

ASCO 2021 highlights head and neck cancer: nasopharyngeal carcinoma

Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

ASCO virtual meeting 2020: highlights head and neck cancer

Resistance to immune checkpoint inhibitors. Next steps and combinational approaches

Head and neck cancer revisited

Immunotherapy for head and neck squamous cell carcinoma

Circulating endothelial progenitor cells in castration resistant prostate cancer: a randomized, controlled, biomarker study

Suchergebnisse filtern